Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors
Combination therapy is becoming imperative for the treatment of many cancers, as it provides a higher chance of avoiding drug resistance and tumor recurrence. Among the resistance-conferring factors, the tumor microenvironment plays a major role, and therefore, represents a viable target for adjuvant therapeutic agents. Thus, hypoxia and extracellular acidosis are known to select for the most aggressive and resilient phenotypes and build poorly responsive regions of the tumor mass. Carbonic anhydrase (CA, EC 4.2.1.1) IX isoform is a surficial zinc metalloenzyme that is proven to play a central role in regulating intra and extracellular pH, as well as modulating invasion and metastasis processes. With its strong association and distribution in various tumor tissues and well-known druggability, this protein holds great promise as a target to pharmacologically interfere with the tumor microenvironment by using drug combination regimens. In the present review, we summarized recent publications revealing the potential of CA IX inhibitors to intensify cancer chemotherapy and overcome drug resistance in preclinical settings.
Citations by journals
1
2
3
|
|
Cancers
|
Cancers
3 publications, 14.29%
|
Molecules
|
Molecules
2 publications, 9.52%
|
Journal of Enzyme Inhibition and Medicinal Chemistry
|
Journal of Enzyme Inhibition and Medicinal Chemistry
2 publications, 9.52%
|
Archiv der Pharmazie
|
Archiv der Pharmazie
2 publications, 9.52%
|
Pharmaceuticals
|
Pharmaceuticals
1 publication, 4.76%
|
Biomedicines
|
Biomedicines
1 publication, 4.76%
|
International Journal of Molecular Sciences
|
International Journal of Molecular Sciences
1 publication, 4.76%
|
Scientific Reports
|
Scientific Reports
1 publication, 4.76%
|
Sensors and Actuators, B: Chemical
|
Sensors and Actuators, B: Chemical
1 publication, 4.76%
|
Journal of Personalized Medicine
|
Journal of Personalized Medicine
1 publication, 4.76%
|
Cancer Medicine
|
Cancer Medicine
1 publication, 4.76%
|
Expert Opinion on Therapeutic Targets
|
Expert Opinion on Therapeutic Targets
1 publication, 4.76%
|
Advanced Functional Materials
|
Advanced Functional Materials
1 publication, 4.76%
|
Steroids
|
Steroids
1 publication, 4.76%
|
Materials Advances
|
Materials Advances
1 publication, 4.76%
|
1
2
3
|
Citations by publishers
1
2
3
4
5
6
7
8
9
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
9 publications, 42.86%
|
Wiley
|
Wiley
4 publications, 19.05%
|
Taylor & Francis
|
Taylor & Francis
3 publications, 14.29%
|
Elsevier
|
Elsevier
2 publications, 9.52%
|
Springer Nature
|
Springer Nature
1 publication, 4.76%
|
Royal Society of Chemistry (RSC)
|
Royal Society of Chemistry (RSC)
1 publication, 4.76%
|
1
2
3
4
5
6
7
8
9
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.